May 1st 2024
The combination of pembrolizumab, trastuzumab, and chemotherapy showed significant improvement in overall survival vs placebo in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
CheckMate 648 trial of Nivolumab Plus Ipilimumab or Chemo in ESCC Continues to Show Survival Benefit
January 20th 2023Nivolumab with chemotherapy or ipilimumab continued to have a clinically meaningful survival benefit vs with chemotherapy alone in patients with treatment-naïve advanced esophageal squamous cell carcinoma.
Read More
RenovoTAMP Supports Gemcitabine Delivery and Decreases AEs in Pancreatic Cancer
January 19th 2023A substudy of the TIGeR-PaC trial showed that treatment with RenovoTAMP may increase local gemcitabine delivery and decrease the debilitating adverse events associated with intravenous administration in pancreatic cancer.
Read More
Adjuvant Atezolizumab Plus Bevacizumab Improve RFS in Early-Stage Hepatocellular Carcinoma
January 19th 2023In IMbrave050, the risk of disease recurrence or death was decreased with adjuvant atezolizumab and bevacizumab compared with active surveillance in patients with early-stage hepatocellular carcinoma.
Read More
20 Years of Trials, Hope and Progress for Patients with Pancreatic Adenocarcinoma
December 21st 2022In a comprehensive review of the last 20 years of advancements and challenges in the pancreatic adenocarcinoma landscape, Dr. Tomsilav Dragovich highlights how treatment has evolved for this patient population.
Read More
Zolbetuximab Combo Meets Efficacy End Points in CLDN18.2+, HER2- Gastric/GEJ Cancers
December 19th 2022The GLOW trial of zolbetuximab plus capecitabine and oxaliplatin showed statistically significant progression-free and overall survival rates in CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Read More
FDA Grants FTD to Pelareorep Plus Atezolizumab and Chemotherapy for Advanced PDAC
December 2nd 2022The FDA has granted a fast track designation to the combination of pelareorep and atezolizumab with gemcitabine and nab-paclitaxel for advanced or metastatic pancreatic ductal adenocarcinoma after promising results were presented from the GOBLET study at the SITC Annual Meeting.
Read More